Alimta

... Bloomberg.com: U.S.

Updated: New York: Apr 18 08:00London: Apr 18 13:00Tokyo: Apr 18 21:00 : Regions Top Worldwide Regions Asia Australia & New Zealand Canada Europe Germany Japan Latin America U.K.

U.S.

Markets Economy/Politics Commentary Sports Culture RESOURCES: Bloomberg TV Bloomberg Radio Markets U.S.

E-Mail This Story Printer-Friendly Format Adobe to Buy Macromedia for $3.4 Billion, Adding Flash Web-Design Software Bank of America Profit Rises 75 Percent as FleetBoston Bolsters Results U.S.

Stock-Index Futures Drop; Shares of Intel, General Motors Decline Lilly's 1st-Quarter Profit Rises on Higher Sales, Lower Costs April 18 (Bloomberg) - Eli Lilly & Co., seeking to reduce its reliance on the schizophrenia medicine Zyprexa, said first- quarter profit rose 84 percent because of higher sales and lower expenses.

Net income increased to $736.6 million, or 68 cents a share, from $400.4 million, or 37 cents, a year earlier, when Lilly had acquisition-related costs.

Sales rose 4 percent to $3.5 billion, the Indianapolis-based company said today in a statement distributed by PR Newswire.

Lilly is counting on newer medicines such as the attention- deficit drug Strattera, the cancer treatment Chief Executive Sidney Taurel has said he expects sales from eight products introduced in the last three ye...

... Eli Lilly's 1Q earnings top estimates Search Advanced Search Customer Service Register Subscribe to BW Today's News News Archive News Search Special Reports Lifestyle Newsmaker Videos Markets Stocks Funds Sectors Economy & Bonds Investing Glossary Newsletter Sign-Up BUSINESS DIRECTORY Find local experts in: PREMIUM CONTENT MBA Insider ONLINE FEATURES Past Covers Columnists Book Reviews Newsletters BLOGS Brand New Day Deal Flow Tech Beat Well Spent TECHNOLOGY Product Reviews Science Features Tech Forums INVESTING Annual Reports S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Mutual Funds Info Tech 100 S&P 500/BW 50 B-SCHOOLS MBA Profiles MBA Rankings Who's Hiring Grads BW EXTRAS BW Digital Handheld Edition RSS Feeds Reprints/Permissions Conferences Investor Workshops The Associated Press/INDIANAPOLIS, Ind.

Eli Lilly's 1Q earnings top estimates • Find More Stories Like This TODAY'S HEADLINES Praying for Good Earnings The Boss on the Sidelines Tip For the Board: "Don't Assume" "Sarbanes-Oxley Is Not Bad" Denny Hastert's Late Payment In Iraq, Security in Name Only Tech's Gathering Gloom The Old IT Is Dead.

Long Live the New No Quarter in This Telecom Tussle The Web's Future Is You What the Boys of Yahoo See Coming WiMax Fever at Intel Watchdogs With Eyes Wide Shut Reweaving BW Online's Web 20 The Softness in So...

... Research and Markets: Extensive Review and Analysis of Developments and R&D in Breast Cancer Field Research and Markets: Extensive Review and Analysis of Developments and R&D in Breast Cancer Field Research and Markets logo.

(PRNewsFoto) LONDON XEN 08/20/2004 DUBLIN, Ireland, April 15 /PRNewswire/ - Research and Markets (http://www.researchandmarkets.com/reports/c15845 ) has announced the addition of Business Development and R&D Database: Breast cancer to their offering.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH ) "Business Development and R&D Database: Breast Cancer" will provide you with both an update and a complete structure on competitors in this field and their recent advances on breast cancer drug development.

Including R&D from industry as well as academic efforts connected to the private sector.

This report has been compiled to enable your independent and unbiased analysis of progress, pitfalls and competition of drugs for the treatment of breast cancer.

Information on breast cancer in the database has carefully been selected and structured in the four areas of R&D, business interaction, news and company profiles.

Example of candidates included: The complete number of candidate drugs in clinical research for breast cancer, are more than 150 and some of them are listed below: Abraxane,